Kevin C. Glenn, Ph.D.
Allergenicity/Pipeline Issues Mgmt Lead, Monsanto Company
Expert Bio
Dr. Kevin Glenn is a Monsanto Senior Science Fellow and the Scientific Affairs Pipeline Lead within Monsanto Regulatory. He is author of more than 62 scientific publications and 22 patents, a co-inventor of two cholesterol improving therapeutics, and also the co-inventor of a wound-healing agent.
Dr. Glenn obtained his B.S. degree in microbiology from the California State Polytechnic University, Pomona, and his Ph.D. in cell biology from the University of California, Irvine. He joined Monsanto in 1983 after completing an American Heart Association postdoctoral research fellowship at the University of Washington, Seattle. At Monsanto, he has held several roles, including Acting Director of Cardiovascular Research for G.D. Searle.
Dr. Glenn is past Chair of the International Food Biotechnology Committee of the International Life Sciences Institute (ILSI). Previously he chaired the ILSI Task Force on Nutritional and Safety Assessments of GM Crops and the Subcommittee on DNA/Protein Detection within the industry-wide Agricultural Biotechnology Stewardship Technical Committee (ABSTC).
Studies, Articles and Answers
Showing 1 out of 1 results
Question
A: Yes, there are some published examples of GMO products that, during development, had data collected that stopped further development. One early example was the identification of a Brazil nut protein that, when expressed in soybeans, improved their nutritional quality (increased methionine, an essential amino acid for mammals). This product was never commercialized when it was learned that this protein is associated with Brazil nut food allergic reactions (Nordlee, et al, 1996). Another example started as a very promising lead to protect corn from corn rootworm damage. Farmers were [...]
Business Practices GMOs & Farmers